Isofol Medical AB (publ) (STO:ISOFOL)

Sweden flag Sweden · Delayed Price · Currency is SEK
0.5955
-0.0280 (-4.49%)
Feb 5, 2026, 5:29 PM CET
-71.91%
Market Cap167.40M -53.0%
Revenue (ttm)n/a
Net Income-54.49M
EPS-0.29
Shares Out281.11M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume599,084
Average Volume401,164
Open0.6065
Previous Close0.6235
Day's Range0.5900 - 0.6270
52-Week Range0.5900 - 2.4400
Beta0.92
RSI28.59
Earnings DateFeb 18, 2026

About Isofol Medical AB

Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 6
Stock Exchange Nasdaq Stockholm
Ticker Symbol ISOFOL
Full Company Profile

Financial Performance

Financial Statements